"The submission of our NDA for ACER-001 marks an important step toward bringing this potential alternative treatment option to patients with UCDs," said Chris Schelling, Chief Executive Officer and Founder of Acer . "We look forward to working with the FDA through the review process and will continue advancing our preparations for a potential launch of ACER-001, while also assisting Relief toward regulatory submissions in Europe."
Jack Weinstein, Chief Financial Officer and Treasurer of Relief Therapeutics , added, "We are excited about the progress made to date in support of a potential regulatory approval of ACER-001 for UCDs in the U.S. With the NDA now submitted, we will continue our efforts to back ACER-001's development in Europe by targeting submission of a Marketing Authorization Application (MAA) for the treatment of UCDs in Europe by the end of 2021."
$ACER
ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.